Circulating tumor cell (CTC)‐biomarkers are identified to stratify cancer patients for an effective combination of tumor‐initiating stem‐like cell (TIC)‐specific, repurposed federal drug administration (FDA)‐approved drugs identified by a CD133 (+) cell viability screen, a NANOG expression screen, and a drug combination screen. The gene discussed is PROM1; the disease is neoplasm.